{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T10:05:04Z","timestamp":1794391504449,"version":"4.9.0"},"reference-count":42,"publisher":"Cambridge University Press (CUP)","issue":"11","license":[{"start":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T00:00:00Z","timestamp":1497484800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>The 7 and 13-valent pneumococcal conjugate vaccines (PCVs) have reduced the incidence of invasive pneumococcal disease (IPD) in children in many countries. The objective of this work was to assess the impact of PCVs and potential herd-protection in older adults in Ireland. IPD notification and typing data from adults \u2a7e65 years of age from July 2007 to June 2016 was assessed using national surveillance data. There was a 94% reduction in PCV7 serotypes from 2007\u20132008 to 2015\u20132016, incidence rate ratio (IRR 0\u00b705, <jats:italic>P<\/jats:italic> &lt; 0\u00b70001). However, there was no decline in the additional PCV13 (PCV13-7) serotypes over the same period (IRR 0\u00b790) nor in comparison with the pre-PCV13 period 2009\u20132010 (IRR 0\u00b792). The incidence of serotypes in the 23-valent pneumococcal polysaccharide vaccine only (PPV23-PCV13) and non-vaccine types (NVTs) increased significantly (IRR 2\u00b717, <jats:italic>P<\/jats:italic> = 0\u00b70002 and IRR 3\u00b743, <jats:italic>P<\/jats:italic> = 0\u00b70001 respectively). Consequently, the overall IPD incidence rate in adults has remained relatively unchanged (from 28\u00b766\/100 000 to 28\u00b788\/100 000, IRR 1\u00b701, <jats:italic>P<\/jats:italic> = 0\u00b79477). Serotype 19A and NVTs were mainly responsible for penicillin resistance in recent years. The decline of PCV7 serotypes indicate that the introduction of PCV7 resulted in herd-protection for adults. However, increases in PPV23-PCV13 and NVTs suggest that changes in vaccination strategy amongst older adults are needed to build on the success of PCVs in children.<\/jats:p>","DOI":"10.1017\/s0950268817001194","type":"journal-article","created":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T10:06:00Z","timestamp":1497521160000},"page":"2390-2399","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":46,"title":["The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect?"],"prefix":"10.1017","volume":"145","author":[{"given":"M.","family":"CORCORAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"VICKERS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"MERECKIENE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"MURCHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"COTTER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"FITZGERALD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"MCELLIGOTT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"CAFFERKEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"O'FLANAGAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"CUNNEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"HUMPHREYS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2017,6,15]]},"reference":[{"key":"S0950268817001194_ref22","unstructured":"National Immunisation Advisory Council. Chapter 3 Immunisation of Immunocompromised Persons. 2015 (http:\/\/www.hse.ie\/eng\/health\/immunisation\/hcpinfo\/guidelines\/chapter3.pdf). Accessed 02 February 2016."},{"key":"S0950268817001194_ref42","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1087625"},{"key":"S0950268817001194_ref32","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u2a7e65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"37","author":"Tomczyk","year":"2014","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"S0950268817001194_ref24","first-page":"743","article-title":"Pneumococcal vaccination rates in adults in Germany","volume":"110","author":"Theidel","year":"2013","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"S0950268817001194_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40471-016-0077-5"},{"key":"S0950268817001194_ref35","unstructured":"Wayne P . Performance standards for antimicrobial susceptibility testing; twenty-third information supplement. CLSI document. M100-S23. Clinical Laboratory Standards Institute 2013."},{"key":"S0950268817001194_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.05.028"},{"key":"S0950268817001194_ref40","unstructured":"Irish Thoratic Society. Lung disease in Ireland \u2013 prevalence and trends: implications for work force planning (http:\/\/www.irishthoracicsociety.com\/images\/uploads\/Lung%20Disease%20in%20Ireland%20December%202013.pdf). Accessed 27 March 2017."},{"key":"S0950268817001194_ref16","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1118593"},{"key":"S0950268817001194_ref21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051460"},{"key":"S0950268817001194_ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.05.010"},{"key":"S0950268817001194_ref25","unstructured":"Public Health England. Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2015 to March 2016 (https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/540290\/hpr2416_ppv.pdf). Accessed 05 July 2016."},{"key":"S0950268817001194_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71081-3"},{"key":"S0950268817001194_ref15","first-page":"1","article-title":"Surveillance of vaccination coverage among adult populations \u2014 United States, 2014","volume":"1","author":"Williams","year":"2016","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"S0950268817001194_ref37","first-page":"48","article-title":"The acceptability of pneumococcal vaccine to older persons in Ireland","volume":"93","author":"Bedford","year":"2000","journal-title":"Irish Medical Journal"},{"key":"S0950268817001194_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.trivac.2016.04.004"},{"key":"S0950268817001194_ref36","unstructured":"Public Health England. Quarterly vaccination coverage statistics for children aged up to five years in the UK (COVER programme): January to March 2015 [September 2016]; Available from: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/438439\/hpr2215_cover.pdf."},{"key":"S0950268817001194_ref2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1907.121830"},{"key":"S0950268817001194_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.068"},{"key":"S0950268817001194_ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408544"},{"key":"S0950268817001194_ref12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu524"},{"key":"S0950268817001194_ref20","unstructured":"Health Protection Surveillance Centre. Quarterly Reports on Invasive Pneumococcal Disease. 2016 (https:\/\/www.hpsc.ie\/A-Z\/VaccinePreventable\/PneumococcalDisease\/Publications\/QuarterlyReportsonInvasivePneumococcaDisease\/File,15801,en.pdf). Accessed 04 August 2016."},{"key":"S0950268817001194_ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001517"},{"key":"S0950268817001194_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.epidem.2015.01.001"},{"key":"S0950268817001194_ref39","unstructured":"European Statistics- Europa. Respiratory diseases statistics.2016 (http:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php\/Respiratory_diseases_statistics). Accessed 27 March 2017."},{"key":"S0950268817001194_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70044-7"},{"key":"S0950268817001194_ref13","unstructured":"European Centre for Disease Control. Recommended immunisations for pneumococcal disease. 2016 (http:\/\/vaccine-schedule.ecdc.europa.eu\/Pages\/Scheduler.aspx). Accessed 1 September 2016."},{"key":"S0950268817001194_ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0157-1"},{"key":"S0950268817001194_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62225-8"},{"key":"S0950268817001194_ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-010-1108-7"},{"key":"S0950268817001194_ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1147-x"},{"key":"S0950268817001194_ref33","unstructured":"European Commission. Amending Decision 2002\/253\/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119\/98\/EC of the European Parliament and of the Council. Section L159\/72. Official Journal of the European Union. 2002 [June 2016]. Available from: http:\/\/ec.europa.eu\/health\/ph_threats\/com\/docs\/1589_2008_en.pdf."},{"key":"S0950268817001194_ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2006.06.007"},{"key":"S0950268817001194_ref1","unstructured":"World Health Organisation. Priority medicines for Europe and the world \u2018a public health approach to innovation\u2019 (http:\/\/www.who.int\/medicines\/areas\/priority_medicines\/BP6_22Pneumo.pdf). May 2013."},{"key":"S0950268817001194_ref19","unstructured":"Health Protection Surveillance Centre. Immunisation uptake report for Ireland - A report by the Health Protection Surveillance Centre-2016 (http:\/\/www.hpsc.ie\/A-Z\/VaccinePreventable\/Vaccination\/ImmunisationUptakeStatistics\/Immunisationuptakestatisticsat12and24monthsofage\/AnnualReports\/File,15662,en.pdf). Accessed 31 August 2016."},{"key":"S0950268817001194_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.085"},{"key":"S0950268817001194_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.09.019"},{"key":"S0950268817001194_ref26","unstructured":"Joint Committee on Vaccination and Immunisation. Interim JCVI statement on adult pneumococcal vaccination in the UK \u2013 November 2015 (https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/477966\/JCVI_pnemococcal.pdf). Accessed 03 September 2016."},{"key":"S0950268817001194_ref41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010105"},{"key":"S0950268817001194_ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131494"},{"key":"S0950268817001194_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.01.030"},{"key":"S0950268817001194_ref5","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00024-15"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268817001194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T19:35:38Z","timestamp":1555529738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268817001194\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,15]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0950268817001194"],"URL":"https:\/\/doi.org\/10.1017\/s0950268817001194","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,15]]},"assertion":[{"value":"Copyright \u00a9 Cambridge University Press 2017\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}